Slide 1: Half-year results — key points
& 2011 half-year financials Company overview CG COMPUMEDICS Half-year results — key points * Solid performance despite ongoing challenging external economic factors (including a high Aussie dollar and sluggish US market for medical capital equipment) + All key growth strategies advanced during the h
Slide 2: Half-year results — review
Half-year results — key points Sales force in USA almost doubled through Jan 2011 to exploit the momentum of the expected recovery in the US. Impact of these changes are anticipated in future financial periods Transition from predominantly engineering focus to sales and marketing focus continues so
Slide 3: Half year results - review; Resilience and growth
Half year results - review Loss after tax of $1.1m largely attributable to an adverse $1.6m FX charge in Hi FY11 due to currency movements, compares to profit after tax of $0.3m in H1 FY10 Operating cash at $(0.5m) for H1 FY11 was adverse to H1 FY10 result of $0.8m. Two large payments from European
Slide 4: Financials — revenue and EBITDA history
Goo DIC: Financials — revenue history 25 GFC impact Revenues stable and! 20 gi N oe HI 15 10 5 i) H1 2008 H1 2009 H1 2010 H1 2011 O Sales as reported & Sales constant currency Financials — EBITDA history EBITDA as reported and with the period-end unrealised FX adjustment removed 3 2.5 CHALLENGE: Gro
Slide 5: Established Client Profile; Product Growth Drivers
Established Client Profile oe | 0 Hospital Melbourne A. wes Austin Heath fa (PP MAYS sat STANFORD UNIVERSITY ® tien W Providen 19 OF MICHIGAN BAA Medical ¢ me a: Mo Product Growth Drivers Sleep Disorders: Treatment Starts with Diagnosis“ Sleep apnoea & Co-morbidities . + Sleep apnoea represents a yo
Slide 6: Sleep co-morbidities & EEG disorders prevalence
Product Growth Drive! Sleep Co-morbidities & EEG disorders: Prevalence underpins future outlook Drug Resistant Hypertension 1] je ‘Congestive Heart Failure [3] ‘Type 2 Diabetes [4] Stroke & Tran nt Ischemic Attack [5] Pacemakers [6] SLEEP APNOEA Atrial Fibrillation [7] All Hypertension [6] Coronary
Slide 7: New market opportunity — long-term EEG monitoring
Product Growth Drivers New market opportunity — neurological disorders including long-term EEG monitoring (LTEM) Compumedics Neurology Diagnostic Equipment Routine clinical EEG testing ica) Long Term Monitoring (epilepsy) u Research fEEG, EEG, EP a + Existing global market - NEW product, NEW global
Slide 8: Sleep Treatment; Market & Growth Outlook
Sleep Treatment - + Compumedics introduces its first device for the sleep- treatment market, Somnilink® SPAP® + Sleep treatment is more than 10 times the size of the global sleep diagnostic market at approximately USD3bn annually + Compumedics has over 4,000 beds of sleep diagnostic equipment world
Slide 9: Strategic Growth Objectives
Strategic Growth Objectives ¢ Go-Forward Strategic Mission: “ Expand Compumedics sales force 2 to 3-fold as Compumedics augments its technological leadership with sales and marketing leadership. * Achieve substantial and rapid commercialization of Compumedics new breakthrough sleep treatment SPAP te
Slide 10: Strategic Growth Execution; Capitalization Pathways
Strategic Growth Execution > Focused & Market Driven 7 . * Avre-focus on the front end of the business ‘S&M and R&D expenses to reveneus % (forecast 30% + Harvest existing product 25% _.—> and technology offering 20% 15% SS + Hold R&D spending to 10% renew and refresh 5% 0% T * Deliver increasing SN
Slide 11: What to look for from Compumedics
Gcompumenics What to look for from Compumedics + Establishment of new LTEM reference sites + Expansion of LTEM sales force * Establishment of home sleep testing distribution channels + Increased core business sales corresponding to expanded sales force + Establishment of new SPAP® sleep treatment di
Slide 12: For personal use only
For personal use only